Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 1/20 | 0.32 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | PPIA | P62937 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15733008 | 0.79 | DGAT1 (0.49) | RHEBROCK1DGAT1PTGER1DHODH | |
| SCHEMBL17250101 | 0.70 | DGAT1 (0.60) | DGAT1 | |
| SCHEMBL15732994 | 0.70 | DGAT1 (0.68) | RHEBROCK1DGAT1PTGER1SRD5A2 | |
| SCHEMBL15733000 | 0.68 | ROCK1 (0.44) | ROCK1PTGER1 | |
| SCHEMBL15733044 | 0.66 | DGAT1 (0.71) | DGAT1 | |
| SCHEMBL15742640 | 0.65 | RHEB (0.34) | RHEBROCK1DGAT1 | |
| SCHEMBL15745369 | 0.63 | KCNH2 (0.40) | ROCK1DGAT1SRD5A2ERBB2 | |
| SCHEMBL31116667 | 0.62 | ROCK1 (0.61) | ROCK1SRD5A2 | |
| SCHEMBL14136848 | 0.61 | DGAT1 (0.59) | ROCK1DGAT1DHODH | |
| SCHEMBL31460315 | 0.58 | ROCK1 (0.58) | ROCK1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174049-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180099979-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2018-04-12 | — | — | US | disclosed |
| US-20180099979-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099979-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, DLAT | RHEB 2145/4885ROCK1 1566/4885DGAT1 1/4885 |
| US-10174049-B2 | Compounds as diacylglycerol acyltransferase inhibitors | DGAT1, DGAT2, LCAT | RHEB 2261/4885ROCK1 1221/4885DGAT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.